Power morcellation FDA safety communications changed how gynaecology departments think about laparoscopic fibroid and uterus removal. This article summarises, in general terms, what the warnings said, what professional guidance recommends about risks and contained techniques, and how a hospital can write a compliant internal policy. It is not clinical or legal advice; please read the current primary documents.
What the FDA communications said
In 2014 the US Food and Drug Administration issued safety communications on laparoscopic power morcellation during hysterectomy and myomectomy for fibroids. The concern was that an unsuspected uterine sarcoma, which can look like a fibroid, might be cut and spread within the abdomen, which could worsen the outlook for the patient.
The agency discouraged the use of power morcellation in many women, added strong warnings to labelling and later described contained systems as an area of device development. The communications are US regulatory documents, so UAE users should check the position of their own authority.
Understanding power morcellation risks
The main risks discussed are dissemination of unsuspected malignant tissue and of benign tissue fragments, as well as injury to organs by the blade and spread of fluid. Pre-operative assessment cannot exclude every sarcoma, which is why guidance concentrates on patient selection, counselling and technique rather than on any single device.
Professional societies have issued recommendations that emphasise individual risk assessment, thorough pre-operative evaluation, informed consent that explains the uncertainty and the use of contained approaches when morcellation is chosen. Read the current statements from the societies relevant to your practice.
Contained morcellation: bags and techniques
Contained uterine morcellation places the specimen in an enclosed bag and morcellates it inside. The bag keeps fragments away from the peritoneal cavity, although it does not remove the need for judgement. BOWA's MetraBag pro is a sterile 3.5-litre bag inserted through a 10 mm trocar, with three closable ports and CO2 insufflation, and is intended to reduce the risk of abnormal cell dissemination.
It can be combined with the reusable ERGO 300 morcellator, which has 12 and 15 mm working diameters. For technique and workflow see contained morcellation explained and our overview of in-bag morcellation.
Building a hospital morcellation policy
A hospital policy usually covers who may perform morcellation, how patients are selected and counselled, what imaging and tissue sampling are required beforehand, whether contained techniques are mandatory and how cases are documented and audited.
Equipment governance is also part of it: approved devices, training, reprocessing, and incident reporting. Align the policy with your regulator's expectations and with your multidisciplinary team. For purchasing, see the power morcellator buying guide.
Consent, documentation and audit
Informed consent should explain, in plain language, that fibroid-like tumours cannot always be distinguished from malignancy before surgery, what alternatives exist and whether containment will be used. Record the discussion and the choice in the notes.
Audit gives the policy teeth. Track the number of morcellation cases, how many used containment, any bag failure or conversion, and histology results. Review the figures at a regular governance meeting and share learning with the team.
Practical next steps for departments
Hold a multidisciplinary review, define alternatives to morcellation such as vaginal or minilaparotomy extraction, and record the discussion with the patient. Test the bag and morcellator in a simulation before first use.
Beckfinity can support departments evaluating contained morcellation equipment; please request a quote or consultation.
Frequently asked questions
What did the FDA say about power morcellation?
It issued safety communications in 2014 about the risk of spreading unsuspected cancer and discouraged the use of power morcellators in many women.
Is contained morcellation safer?
Containment is intended to reduce the spread of fragments, but it does not remove the need for patient selection and counselling.
Do FDA rules apply in the UAE?
No, they are US regulations. Check requirements with the relevant UAE authority and professional bodies.
What should a morcellation policy include?
Patient selection, counselling and consent, containment requirements, approved devices, training and audit.
Related articles
- Choosing a Tissue Retrieval Bag for Gynecologic Laparoscopy
- Uterine Manipulator Types and Names: A Guide for Surgeons and Buyers
- What Is Office Hysteroscopy? Procedure, Setting and Equipment Explained
- Power Morcellator Buying Guide for Gynaecology Departments
- Best Practice in Outpatient Hysteroscopy: What Clinics Must Equip
- Anchor Tissue Retrieval Bag vs Other Brands: How OR Buyers Compare
- Operative Hysteroscopy: Choosing Resectoscopes, Energy and Pumps
- Care and Maintenance of Surgical Instruments: A Practical OR and CSSD Guide
- Portable Suction Machine Guide: Flow, Vacuum, Canisters and Battery
- Choosing a medical equipment supplier in the UAE: a buyer's checklist